Empowered Funds LLC purchased a new position in Sage Therapeutics, Inc. (NASDAQ:SAGE – Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 16,680 shares of the biopharmaceutical company’s stock, valued at approximately $91,000.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. boosted its position in shares of Sage Therapeutics by 66.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 11,742 shares of the biopharmaceutical company’s stock valued at $85,000 after buying an additional 4,672 shares during the last quarter. Creative Planning purchased a new position in shares of Sage Therapeutics during the third quarter valued at approximately $88,000. Quest Partners LLC boosted its position in shares of Sage Therapeutics by 56.3% during the third quarter. Quest Partners LLC now owns 18,381 shares of the biopharmaceutical company’s stock valued at $133,000 after buying an additional 6,618 shares during the last quarter. Intech Investment Management LLC purchased a new position in shares of Sage Therapeutics during the third quarter valued at approximately $146,000. Finally, SG Americas Securities LLC boosted its position in shares of Sage Therapeutics by 57.7% during the fourth quarter. SG Americas Securities LLC now owns 22,498 shares of the biopharmaceutical company’s stock valued at $122,000 after buying an additional 8,228 shares during the last quarter. Institutional investors own 99.22% of the company’s stock.
Sage Therapeutics Stock Performance
NASDAQ:SAGE opened at $7.31 on Friday. Sage Therapeutics, Inc. has a one year low of $4.62 and a one year high of $23.22. The firm has a market cap of $449.42 million, a price-to-earnings ratio of -1.11 and a beta of 0.94. The firm’s fifty day moving average is $6.55 and its two-hundred day moving average is $6.80.
Wall Street Analyst Weigh In
A number of analysts recently commented on SAGE shares. Stifel Nicolaus dropped their price target on Sage Therapeutics from $10.00 to $6.00 and set a “hold” rating on the stock in a report on Monday, December 16th. Canaccord Genuity Group dropped their price target on Sage Therapeutics from $9.00 to $8.00 and set a “hold” rating on the stock in a report on Wednesday, February 12th. Royal Bank of Canada upgraded Sage Therapeutics from an “underperform” rating to a “sector perform” rating and set a $4.00 price target on the stock in a report on Thursday, November 21st. Needham & Company LLC reiterated a “hold” rating on shares of Sage Therapeutics in a report on Wednesday, February 12th. Finally, Scotiabank dropped their price target on Sage Therapeutics from $14.00 to $12.00 and set a “sector outperform” rating on the stock in a report on Wednesday, February 12th. Three equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, Sage Therapeutics has a consensus rating of “Hold” and a consensus target price of $9.65.
View Our Latest Stock Analysis on Sage Therapeutics
About Sage Therapeutics
Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.
Read More
- Five stocks we like better than Sage Therapeutics
- What is the Nikkei 225 index?
- Unity Stock: Is a True Turnaround Finally Taking Shape?
- Canada Bond Market Holiday: How to Invest and Trade
- DuPont’s Electronics Spinoff: The Start of Something Big
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- The Trade Desk Crashes on Earnings, But Growth Catalysts Persist
Want to see what other hedge funds are holding SAGE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sage Therapeutics, Inc. (NASDAQ:SAGE – Free Report).
Receive News & Ratings for Sage Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.